DescriptionPeter Doshi discusses recent changes to two of the EMA’s policies affecting access to its archives (policy 0043) and publication of new clinical data (policy 0070). The former is a permanent revision while the latter is temporary. Both policies reduce transparency by restricting access to drug data critical to independent research initiatives associated with safety, efficacy, and appropriate trial methodology.
CitationDoshi, P. (2018) EMA scales back transparency initiatives because of workload. BMJ. 362:k3513. DOI: 10.1136/bmj.k3513
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/8133
The following license files are associated with this item: